Stock listing

BOATS:IMNM Immunome, Inc. Stock

US listing (BOATS) of Immunome, Inc. · home listing NASDAQ:IMNM

Follow Immunome, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:IMNM

$15.69 USD -1.09 (-6.5%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:IMNM

Past year -10.4% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$15.55 – $16.73 USDNov 20, 2026
Volume
1.06M sharesNov 20, 2026
Market cap
$1.85B USDAt the close on Nov 20, 2026 · price × 118.1M shares outstanding
52-week range
$15.55 – $30.06 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$28.67M USDMedian day 1.17M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Immunome, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:IMNM · Home$15.69 USD-1.09 (-6.5%)1,056,097$16.45$16.73$15.55$16.78Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:IMNM · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$15.69-1.09-6.5%$16.45$16.73$15.551,056,097
$16.78-0.40-2.3%$17.16$17.89$16.651,412,326
$17.18-0.43-2.4%$17.67$18.16$16.781,027,498
$17.61-1.16-6.2%$18.50$19.15$17.551,518,971
$18.77+0.07+0.4%$18.62$18.81$18.10951,066
$18.70-0.37-1.9%$18.74$19.06$18.021,658,580
$19.07+0.42+2.3%$18.81$19.29$18.71872,891
$18.65-0.71-3.7%$18.11$19.13$18.111,253,489
$19.36+0.65+3.5%$18.90$19.79$18.461,376,706
$18.71+0.805+4.5%$18.21$18.95$17.321,330,509
$17.91-1.615-8.3%$19.38$19.41$17.292,206,706
$19.52-0.79-3.9%$20.64$22.77$18.473,321,760
$20.31+0.72+3.7%$19.81$20.43$19.781,853,935
$19.59+1.38+7.6%$18.42$19.77$18.402,282,696
$18.21-0.08-0.4%$18.25$18.98$17.821,270,371
$18.29-0.47-2.5%$18.88$19.30$18.11877,800
$18.76-0.01-0.1%$18.50$18.91$18.25952,015
$18.77+0.88+4.9%$17.95$19.00$17.501,225,654
$17.89-0.10-0.6%$17.99$18.35$17.70910,525
$17.99-0.27-1.5%$18.13$18.25$17.651,378,899
$18.26+0.26+1.4%$17.78$18.30$17.591,761,590
$18.00+0.08+0.4%$17.99$18.44$17.851,545,126
$17.92+1.15+6.9%$16.74$18.27$16.552,029,591
$16.77+0.30+1.8%$16.60$16.92$16.441,139,956
$16.47-0.93-5.3%$17.40$17.40$16.411,297,600
$17.40+0.20+1.2%$17.31$17.61$17.081,621,100
$17.20-0.38-2.2%$17.35$18.05$17.131,154,900
$17.58-1.57-8.2%$19.06$19.16$17.432,198,600
$19.15-0.40-2.0%$19.42$19.73$19.08835,700
$19.55+0.24+1.2%$19.05$19.72$18.88998,000
$19.31+0.215+1.1%$18.88$19.35$18.522,131,000
$19.10-0.215-1.1%$18.94$19.56$18.941,161,000
$19.31-1.86-8.8%$21.35$21.43$18.922,310,800
$21.17+0.27+1.3%$20.79$21.48$20.671,216,200
$20.90+0.010.0%$21.33$21.46$20.821,171,600
$20.89-0.62-2.9%$21.17$21.49$20.711,096,800
$21.51-0.38-1.7%$22.15$22.56$21.511,306,000
$21.89+0.21+1.0%$21.64$22.01$21.36917,000
$21.68+0.27+1.3%$21.24$21.81$20.85945,200
$21.41-0.93-4.2%$22.43$22.65$21.152,421,600
$22.34-1.90-7.8%$24.24$24.34$22.212,697,400
$24.24-1.51-5.9%$25.88$25.94$24.042,270,600
$25.75+0.68+2.7%$25.17$25.81$25.091,064,500
$25.07+1.10+4.6%$24.63$25.26$24.191,180,500
$23.97+0.04+0.2%$24.01$24.24$23.363,962,500
$23.93+0.47+2.0%$24.10$24.64$23.77890,800
$23.46-0.49-2.0%$24.29$24.75$23.361,317,800
$23.95-0.60-2.4%$24.44$24.48$23.551,332,000
$24.55-0.12-0.5%$24.65$25.26$24.40744,600
$24.67-0.30-1.2%$25.32$25.73$24.60692,600
$24.97-1.15-4.4%$25.69$26.08$24.91729,900
$26.12-0.69-2.6%$26.43$26.99$26.10784,100
$26.81+0.05+0.2%$26.15$27.25$25.91828,600
$26.76-0.40-1.5%$26.68$27.14$26.66562,300
$27.16-0.17-0.6%$27.60$28.27$26.67796,100
$27.33+0.265+1.0%$27.56$28.49$26.81811,100
$27.07-0.345-1.3%$27.23$27.31$26.64700,200
$27.41-0.16-0.6%$27.48$27.63$27.001,050,700
$27.57-1.30-4.5%$28.45$28.77$27.40783,500
$28.87+0.12+0.4%$28.57$29.11$28.351,055,500
$28.75-0.635-2.2%$29.34$29.39$28.62558,800
$29.39+1.375+4.9%$27.88$29.72$27.881,928,300
$28.01-0.51-1.8%$28.48$28.85$27.641,355,400
$28.52+0.44+1.6%$28.46$29.30$28.13846,500
$28.08-1.745-5.9%$29.13$29.15$27.891,025,500
Ticker
BOATS:IMNM
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
BOATS
Currency
USD

What changed lately

Latest news

All Immunome, Inc. news

Immunome, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
30 in the last 12 months · 135 in all · newest Nov 18, 2026 · oldest 2020
Decks
37 decks · latest October 2026

Where Immunome, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:IMNM · Home listingNASDAQUnited StatesUSD
BOATS:IMNM · This pageBOATSUnited StatesUSD

Valuation

Price/book 4.1× against a median of 4.9×: 3rd lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$1.40B USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
4.1×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.49

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Immunome, Inc. · NASDAQ:IMNMUS$1.85BUS$1.40Bn/an/an/a4.1×n/a0.0×1.49
Shanghai Henlius Biotech, Inc. Class H · HKEX:2696US$1.91BUS$2.36B14.7×2.1×12.3×2.8×11.7%0.9×n/a
Trevi Therapeutics, Inc. · NASDAQ:TRVIUS$1.90BUS$1.60Bn/an/an/a6.3×n/a0.0×1.22
Biohaven Ltd. · NYSE:BHVNUS$1.87BUS$1.71Bn/an/an/an/an/an/a1.19
BioCryst Pharmaceuticals, Inc. · NASDAQ:BCRXUS$1.86BUS$1.88Bn/a1.9×n/an/a−37.4%n/a0.62
Zymeworks Inc. · NASDAQ:ZYMEUS$1.84BUS$2.08B42.5×7.8×40.6×7.1×16.3%1.3×0.69
Vera Therapeutics, Inc. · NASDAQ:VERAUS$1.84BUS$1.53Bn/a149×n/a5.5×n/a0.2×1.13
Hemab Therapeutics Holdings, Inc. · NASDAQ:COAGUS$1.84BUS$1.41Bn/an/an/a4.3×n/a0.0×0.61
Braveheart Bio, Inc. · NASDAQ:BRVEUS$1.84BUS$1.71Bn/an/an/a3.7×n/a0.0×n/a
Septerna, Inc. · NASDAQ:SEPNUS$1.84BUS$1.38Bn/a14.3×n/a4.3×−61.3%0.1×0.95
Replimune Group, Inc. · NASDAQ:REPLUS$1.81BUS$1.60Bn/an/an/a8.8×n/a0.5×0.78
Median of the othersUS$1.84BUS$1.66B28.6×7.8×26.4×4.9×−12.9%0.1×0.87

Forecasts

13 strong buy · 3 buy · 1 hold · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
35.20 USD · Analysts' mean
EPS, year to Dec 2026
-2.47 · 13 analysts
Revenue, year to Dec 2026
500K · 8 analysts

Team and board

Officers

OfficerRole
Clay SiegallPresident & Chief Executive Officer
Max RosettChief Financial Officer
Sandra StonemanChief Legal Officer and Corporate Secretary
Roee ShaharEVP, Commercial
Bob LechleiderChief Medical Officer
Jack HigginsChief Scientific Officer
Phil TsaiChief Technical Officer

Board

DirectorRole
Isaac BarchasLead Independent Director and Director
James BoylanDirector
Sandra M. SwainDirector

Events

Next results
Mar 3, 2027 (expected)
QuarterResultsShare move
Q3 2026Nov 9, 2026 · After close−3.7%
Q2 2026Aug 11, 2026 · After close+6.6%
Q1 2026May 7, 2026−3.6%
Q4 2025Mar 3, 2026 · After close+4.5%
Q3 2025Nov 6, 2025 · After close−1.7%
Q2 2025Aug 6, 2025 · After close−5.6%
Q1 2025May 12, 2025 · After close−0.4%
Q4 2024Mar 19, 2025+3.6%
Q3 2024Nov 13, 2024 · After close−3.9%
Q2 2024Aug 12, 2024 · After close+7.0%
All 20 quarters
QuarterResultsShare move
Q1 2024May 14, 2024 · Before open−5.7%
Q4 2023Mar 28, 2024 · After close−10.4%
Q3 2023Nov 9, 2023 · Before open−2.7%
Q2 2023Aug 9, 2023 · Before open−2.1%
Q1 2023May 5, 2023 · Before open−4.1%
Q4 2022Mar 16, 2023 · Before open+9.2%
Q3 2022Nov 14, 2022 · Before open+0.6%
Q2 2022Aug 5, 2022 · Before open+17.4%
Q1 2022May 12, 2022 · Before open+10.4%
Q4 2021Mar 28, 2022 · Before open+23.0%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (October 2026)Investor deck33 slidesOctober 2026
Investor Presentation (September 2026)Investor deck32 slidesSeptember 2026
Investor Presentation (September 2026)Investor deck33 slidesSeptember 2026
2026 American Society of Clinical Oncology (ASCO) Annual MeetingConference14 slidesJun 2, 2026
Investor Presentation (May 2026)Investor deck32 slidesMay 2026
Investor Presentation (April 2026)Investor deck31 slidesApril 2026
Investor Presentation (March 2026)Investor deck32 slidesMarch 2026
44th Annual J.P. Morgan Healthcare Conference (January 2026)Conference32 slidesJanuary 2026
Corporate Update (December 2025)Corporate update24 slidesDec 15, 2025
Investor Presentation (December 2025)Investor deck32 slidesDec 15, 2025
All 37 decks
DeckKindSlidesDate
Investor Presentation (November 2025)Investor deck38 slidesNovember 2025
Investor Presentation (September 2025)Investor deck36 slidesSeptember 2025
ASCO 2025Conference11 slidesJune 2025
Investor Presentation (April 2025)Investor deck35 slidesApril 2025
Investor Presentation (March 2025)Investor deck35 slidesMarch 2025
Investor Presentation (August 2024)Investor deck36 slidesAug 13, 2024
Investor Presentation (July 2024)Investor deck40 slidesJuly 2024
Investor Presentation (May 2024)Investor deck40 slidesMay 2024
Investor Presentation (February 2024)Investor deck40 slidesFeb 8, 2024
Investor Presentation (January 2024)Investor deck35 slidesJan 11, 2024
Investor Presentation (November 2023)Investor deck27 slidesNov 15, 2023
Investor Presentation (November 2023)Investor deck26 slidesNov 15, 2023
Investor Presentation (November 2023)Investor deck27 slidesNov 15, 2023
Merger or Acquisition (July 2023)Merger or acquisition27 slidesJuly 2023
Merger or Acquisition (June 2023)Merger or acquisition27 slidesJun 29, 2023
Investor Presentation (January 2023)Investor deck27 slidesJan 30, 2023
Investor Presentation (January 2023)Investor deck34 slidesJanuary 2023
Investor Presentation (November 2022)Investor deck35 slidesNov 15, 2022
Investor Presentation (June 2022)Investor deck31 slidesJun 9, 2022
Investor Presentation (February 2022)Investor deck38 slidesFeb 8, 2022
Investor Presentation (October 2021)Investor deck34 slidesOct 18, 2021
Investor Presentation (September 2021)Investor deck32 slidesSep 21, 2021
Investor Presentation (July 2021)Investor deck30 slidesJul 20, 2021
Investor Presentation (April 2021)Investor deck38 slidesApr 26, 2021
Investor Presentation (March 2021)Investor deck30 slidesMar 29, 2021
Investor Presentation (March 2021)Investor deck29 slidesMar 16, 2021
Investor Presentation (October 2020)Investor deck33 slidesOct 26, 2020

Open Decks

Financings

RaiseDate
Public offering of common stock
Update: about US$400M · US$21.5 a share · Leerink Partners +6
Dealers: Leerink Partners (lead), J.P. Morgan (lead), TD Cowen (lead), Goldman Sachs & Co. LLC (lead), Guggenheim Securities (lead), Wedbush PacGrow (co-lead), LifeSci Capital (co-lead)
Dec 16, 2025
Public offering of common stock
Closed: US$172.5M raised · US$7.75 a share · J.P. Morgan +4
Dealers: J.P. Morgan (co-lead), TD Cowen (co-lead), Leerink Partners (co-lead), Guggenheim Securities (co-lead), Wedbush PacGrow
Jan 31, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$12.00 a share on Oct 1, 2020.

Price
US$12.00 a share
Shares offered
3,250,000 shares of common stock
Offering size
US$39 million
Underwriters' option
Up to 487,500 more shares
Listing
IMNM on the Nasdaq Capital Market
Underwriters
Ladenburg Thalmann, Chardan · In the order on the cover
Shares delivered
On or about Oct 6, 2020

Steps

StepWhen
Draft sent to the SEC in confidenceAug 12, 2020
Filed publiclySep 9, 2020
Amended onceSep 24, 2020
Shares registered with an exchangeSep 30, 2020
Declared effective by the SECOct 1, 2020
Final prospectus, with the priceOct 5, 2020

Open IPO · From the cover of the final prospectus (424B4) filed Oct 5, 2020

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue6.94M9.04M14.0M6.63M0000
Cost of revenue2.96M2.10M728.0K631.0K755.0K755.0K615.0K521.0K
Gross profit3.99M9.04M14.0M-631.0K-755.0K-755.0K-615.0K-521.0K
Research and development177.3M129.5M23.1M23.3M14.1M7.49M8.82M6.88M
Selling, general and administrative43.8M33.0M19.7M13.6M11.1M4.78M1.52M866.0K
Operating income-224.1M-305.8M-109.5M-36.9M-25.2M-12.3M-10.3M-7.74M
Depreciation and amortization2.47M1.57M457.0K422.0K755.0K755.0K615.0K521.0K
EBITDA-221.6M-304.2M-109.1M-36.5M-24.4M-11.5M-9.73M-7.22M
Interest expense5.00K10.0K21.0K46.0K141.0K
Income before tax-212.4M-293.0M-106.8M-36.9M-24.7M-17.8M-10.4M-7.84M
Income tax000000039.0K
Net income-212.4M-293.0M-106.8M-36.9M-24.7M-17.8M-10.4M-7.84M
Earnings per share, basic-2.43-5.00-5.38-3.09-2.14-5.26-9.55-7.18
Earnings per share, diluted-2.43-5.00-5.38-3.09-2.14-5.26-9.55

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash and equivalents653.5M143.4M98.7M20.3M49.2M39.8M2.54M1.60M
Short-term investments074.0M39.5M0
Receivables289.0K847.0K4.31M850.0K
Inventory-847.0K-4.31M-900.0K
Current assets660.8M221.3M144.7M22.6M56.6M42.9M3.12M2.11M
Property, plant and equipment14.6M10.1M2.07M681.0K855.0K1.53M1.70M2.08M
Total assets683.2M240.2M148.5M24.0M57.9M44.5M5.06M4.45M
Accounts payable3.34M14.2M3.31M2.40M3.08M1.19M548.0K473.0K
Current liabilities45.0M54.3M21.8M7.33M9.73M3.04M1.67M1.56M
Long-term debt134.0K113.0K325.0K
Total debt3.85M4.83M1.65M291.0K317.0K500.0K564.0K1.18M
Total liabilities48.8M59.1M28.7M7.39M9.74M3.18M1.80M29.7M
Shareholders' equity634.3M181.2M119.9M16.7M48.2M41.3M-35.6M-25.2M
Shares outstanding113.1M64.5M43.3M12.1M12.1M10.6M1.10M1.09M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations-190.9M-110.8M-7.57M-28.7M-18.2M-12.1M-9.60M-7.41M
Capital spending-9.69M-7.17M-831.0K-248.0K-79.0K-586.0K-233.0K-228.0K
Free cash flow-200.6M-118.0M-8.40M-28.9M-18.3M-12.7M-9.83M-7.63M
Cash from investing60.8M-85.1M-30.5M-248.0K-79.0K-586.0K-233.0K-228.0K
Cash from financing640.4M240.5M116.4M32.0K27.8M49.9M10.8M-551.0K
Dividends paid-49.0K-4.62M
Share buybacks32.0K-49.0K-35.0K0
Change in cash510.2M44.7M78.4M-28.9M9.46M37.2M941.0K-8.19M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G · Big-stake noticeNov 16, 2026Big-stake noticeSEC
S-3ASR · Registration statementNov 9, 2026Offer documentSEC
S-3ASR · Registration statementNov 9, 2026Offer documentSEC
10-Q · Quarterly reportNov 9, 2026Quarterly reportSEC
8-K · Current reportNov 9, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeOct 30, 2026Big-stake noticeSEC
8-K · Current reportOct 5, 2026Material contractSEC
4 · Change in ownershipSep 15, 2026Insider tradeSEC
144 · Notice of proposed saleSep 11, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
Show 200 filings
FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
4 · Change in ownershipAug 12, 2026Insider tradeSEC
144 · Notice of proposed saleAug 12, 2026Other filingsSEC
S-8 · Registration statement for employee plansAug 11, 2026Offer documentSEC
10-Q · Quarterly reportAug 11, 2026Quarterly reportSEC
8-K · Current reportAug 11, 2026ResultsSEC
4 · Change in ownershipAug 10, 2026Insider tradeSEC
4 · Change in ownershipAug 6, 2026Insider tradeSEC
144 · Notice of proposed saleAug 6, 2026Other filingsSEC
144 · Notice of proposed saleAug 4, 2026Other filingsSEC
4 · Change in ownershipJul 27, 2026Insider tradeSEC
4 · Change in ownershipJul 27, 2026Insider tradeSEC
4 · Change in ownershipJul 27, 2026Insider tradeSEC
4 · Change in ownershipJul 27, 2026Insider tradeSEC
4 · Change in ownershipJul 27, 2026Insider tradeSEC
4 · Change in ownershipJul 27, 2026Insider tradeSEC
4 · Change in ownershipJul 27, 2026Insider tradeSEC
4 · Change in ownershipJul 9, 2026Insider tradeSEC
4 · Change in ownershipJul 7, 2026Insider tradeSEC
4 · Change in ownershipJul 7, 2026Insider tradeSEC
144 · Notice of proposed saleJul 7, 2026Other filingsSEC
144 · Notice of proposed saleJul 6, 2026Other filingsSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
144 · Notice of proposed saleJul 2, 2026Other filingsSEC
144 · Notice of proposed saleJul 2, 2026Other filingsSEC
144 · Notice of proposed saleJun 30, 2026Other filingsSEC
144 · Notice of proposed saleJun 30, 2026Other filingsSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
144 · Notice of proposed saleJun 25, 2026Other filingsSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
144 · Notice of proposed saleJun 15, 2026Other filingsSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
8-K · Current reportJun 12, 2026Meeting outcomeSEC
4 · Change in ownershipJun 9, 2026Insider tradeSEC
4 · Change in ownershipMay 19, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 12, 2026Quarterly reportSEC
8-K · Current reportMay 12, 2026ResultsSEC
ARS · Annual report to shareholdersApr 24, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 24, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 24, 2026Meeting noticeSEC
4 · Change in ownershipApr 3, 2026Insider tradeSEC
4 · Change in ownershipApr 3, 2026Insider tradeSEC
144/A · Notice of proposed sale, amendedApr 3, 2026Other filingsSEC
144 · Notice of proposed saleApr 2, 2026Other filingsSEC
144 · Notice of proposed saleApr 2, 2026Other filingsSEC
4 · Change in ownershipApr 1, 2026Insider tradeSEC
4 · Change in ownershipMar 31, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 26, 2026Big-stake noticeSEC
4 · Change in ownershipMar 23, 2026Insider tradeSEC
144 · Notice of proposed saleMar 20, 2026Other filingsSEC
4 · Change in ownershipMar 12, 2026Insider tradeSEC
S-8 · Registration statement for employee plansMar 3, 2026Offer documentSEC
10-K · Annual reportMar 3, 2026Annual reportSEC
8-K · Current reportMar 3, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
4 · Change in ownershipDec 30, 2025Insider tradeSEC
4 · Change in ownershipDec 23, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedDec 22, 2025Big-stake noticeSEC
4 · Change in ownershipDec 22, 2025Insider tradeSEC
4 · Change in ownershipDec 22, 2025Insider tradeSEC
4 · Change in ownershipDec 22, 2025Insider tradeSEC
4 · Change in ownershipDec 18, 2025Insider tradeSEC
8-K · Current reportDec 17, 2025Current reportSEC
424B5 · ProspectusDec 17, 2025Offer documentSEC
424B5 · ProspectusDec 15, 2025Offer documentSEC
8-K · Current reportDec 15, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeNov 7, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 6, 2025Quarterly reportSEC
8-K · Current reportNov 6, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 7, 2025Big-stake noticeSEC
4 · Change in ownershipSep 11, 2025Insider tradeSEC
10-Q · Quarterly reportAug 6, 2025Quarterly reportSEC
8-K · Current reportAug 6, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeAug 6, 2025Big-stake noticeSEC
4 · Change in ownershipJul 31, 2025Insider tradeSEC
4 · Change in ownershipJul 31, 2025Insider tradeSEC
4 · Change in ownershipJul 31, 2025Insider tradeSEC
4 · Change in ownershipJul 31, 2025Insider tradeSEC
4 · Change in ownershipJul 31, 2025Insider tradeSEC
4 · Change in ownershipJul 31, 2025Insider tradeSEC
4 · Change in ownershipJul 31, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeJul 29, 2025Big-stake noticeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
8-K · Current reportJun 11, 2025Meeting outcomeSEC
4 · Change in ownershipJun 3, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 12, 2025Quarterly reportSEC
8-K · Current reportMay 12, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 12, 2025Big-stake noticeSEC
ARS · Annual report to shareholdersApr 24, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 24, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 24, 2025Meeting noticeSEC
4 · Change in ownershipMar 28, 2025Insider tradeSEC
4 · Change in ownershipMar 26, 2025Insider tradeSEC
4 · Change in ownershipMar 26, 2025Insider tradeSEC
4 · Change in ownershipMar 25, 2025Insider tradeSEC
4 · Change in ownershipMar 25, 2025Insider tradeSEC
S-8 · Registration statement for employee plansMar 19, 2025Offer documentSEC
10-K · Annual reportMar 19, 2025Annual reportSEC
8-K · Current reportMar 19, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedFeb 4, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 3, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeFeb 3, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 30, 2025Big-stake noticeSEC
8-K · Current reportJan 30, 2025Current reportSEC
424B5 · ProspectusJan 30, 2025Offer documentSEC
424B5 · ProspectusJan 29, 2025Offer documentSEC
8-K · Current reportJan 29, 2025ResultsSEC
8-K · Current reportJan 23, 2025Management or board changeSEC
4 · Change in ownershipNov 25, 2024Insider tradeSEC
4 · Change in ownershipNov 25, 2024Insider tradeSEC
4 · Change in ownershipNov 25, 2024Insider tradeSEC
S-3ASR · Registration statementNov 22, 2024Offer documentSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 14, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 13, 2024Quarterly reportSEC
8-K · Current reportNov 13, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 8, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 4, 2024Big-stake noticeSEC
8-K · Current reportOct 29, 2024Acquisition or disposalSEC
SC 13G · Big-stake noticeOct 22, 2024Big-stake noticeSEC
S-3ASR · Registration statementOct 8, 2024Offer documentSEC
8-K · Current reportOct 7, 2024Current reportSEC
4 · Change in ownershipSep 20, 2024Insider tradeSEC
144 · Notice of proposed saleSep 19, 2024Other filingsSEC
SC 13D/A · Big-stake notice, amendedAug 21, 2024Big-stake noticeSEC
4 · Change in ownershipAug 19, 2024Insider tradeSEC
4 · Change in ownershipAug 19, 2024Insider tradeSEC
144 · Notice of proposed saleAug 15, 2024Other filingsSEC
4 · Change in ownershipAug 13, 2024Insider tradeSEC
4 · Change in ownershipAug 13, 2024Insider tradeSEC
4 · Change in ownershipAug 13, 2024Insider tradeSEC
4 · Change in ownershipAug 13, 2024Insider tradeSEC
4 · Change in ownershipAug 13, 2024Insider tradeSEC
4 · Change in ownershipAug 13, 2024Insider tradeSEC
4 · Change in ownershipAug 13, 2024Insider tradeSEC
10-Q · Quarterly reportAug 12, 2024Quarterly reportSEC
8-K · Current reportAug 12, 2024ResultsSEC
4 · Change in ownershipJun 18, 2024Insider tradeSEC
3 · Initial statement of ownershipJun 18, 2024Insider tradeSEC
4 · Change in ownershipJun 18, 2024Insider tradeSEC
4 · Change in ownershipJun 18, 2024Insider tradeSEC
4 · Change in ownershipJun 18, 2024Insider tradeSEC
4 · Change in ownershipJun 18, 2024Insider tradeSEC
4 · Change in ownershipJun 18, 2024Insider tradeSEC
4 · Change in ownershipJun 18, 2024Insider tradeSEC
8-K · Current reportJun 13, 2024Meeting outcomeSEC
4 · Change in ownershipMay 22, 2024Insider tradeSEC
4 · Change in ownershipMay 21, 2024Insider tradeSEC
4 · Change in ownershipMay 17, 2024Insider tradeSEC
424B5 · ProspectusMay 14, 2024Offer documentSEC
10-Q · Quarterly reportMay 14, 2024Quarterly reportSEC
8-K · Current reportMay 14, 2024ResultsSEC
8-K · Current reportApr 30, 2024Management or board changeSEC
4 · Change in ownershipApr 29, 2024Insider tradeSEC
3 · Initial statement of ownershipApr 29, 2024Insider tradeSEC
ARS · Annual report to shareholdersApr 26, 2024Annual reportSEC
DEFA14A · Additional proxy materialApr 26, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 26, 2024Meeting noticeSEC
8-K · Current reportApr 25, 2024Management or board changeSEC
S-3ASR · Registration statementApr 3, 2024Offer documentSEC
S-3ASR · Registration statementApr 3, 2024Offer documentSEC
10-K · Annual reportMar 28, 2024Annual reportSEC
8-K · Current reportMar 28, 2024ResultsSEC
8-K · Current reportMar 26, 2024Acquisition or disposalSEC
4 · Change in ownershipFeb 21, 2024Insider tradeSEC
3 · Initial statement of ownershipFeb 21, 2024Insider tradeSEC
8-K · Current reportFeb 14, 2024Current reportSEC
424B5 · ProspectusFeb 14, 2024Offer documentSEC
424B5 · ProspectusFeb 13, 2024Offer documentSEC

This page holds 200 of 465 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Immunome, Inc.’s releases · as of Nov 4, 2026

Common shares
118,072,943
Fully diluted
118,382,993

Fully diluted

LineSharesAs of
Common shares118,072,943Nov 4, 2026
Options and RSUs310,050Nov 2, 2026

Warrants and options

Lot
Stock options · US$19.59 · expiry not stated
RSUs · expiry not stated

Share count over time

CountShares
Nov 4, 2026118,072,943

Open Cap table

Shareholders

Institutions

HolderSharesValueAs of
T. Rowe Price21.5MUS$464MSep 30, 2026
Fidelity17MUS$366MSep 30, 2026
BlackRock8.93MUS$192MSep 30, 2026
Vanguard7.12MUS$153MSep 30, 2026
Wellington6.04MUS$130MSep 30, 2026
Driehaus Capital Management LLC4.98MUS$107MSep 30, 2026
Primecap Management Co4.64MUS$99.9MSep 30, 2026
State Street4.49MUS$96.6MSep 30, 2026
Redmile Group, LLC4.36MUS$93.8MSep 30, 2026
Enavate Sciences Gp, LLC3.61MUS$77.7MSep 30, 2026
Show 50 holders
HolderSharesValueAs of
Geode Capital2.82MUS$60.6MSep 30, 2026
Hood River Capital Management LLC2.69MUS$57.9MSep 30, 2026
Silverarc Capital Management, LLC2.09MUS$45MSep 30, 2026
Morgan Stanley1.69MUS$36.3MSep 30, 2026
BNP Paribas1.66MUS$35.7MSep 30, 2026
Sofinnova Investments, Inc.1.63MUS$35MSep 30, 2026
JPMorgan1.56MUS$34.2MSep 30, 2026
Goldman Sachs1.43MUS$30.8MSep 30, 2026
Principal1.21MUS$25.9MSep 30, 2026
Readystate Asset Management LP1.09MUS$23.5MSep 30, 2026
Woodline Partners LP1MUS$21.5MSep 30, 2026
Northern Trust998KUS$21.5MSep 30, 2026
Schwab997KUS$21.4MSep 30, 2026
MetLife Investment Management, LLC916KUS$19.7MSep 30, 2026
Pivotal bioVenture Partners Investment Advisor LLC733KUS$15.8MSep 30, 2026
TD702KUS$15.4MSep 30, 2026
Nan Fung Trinity (Hk) LTD621KUS$13.4MSep 30, 2026
Atom Investors LP608KUS$13.1MSep 30, 2026
Bank of America598KUS$12.9MSep 30, 2026
Marshall Wace, LLP518KUS$11.1MSep 30, 2026
UBS490KUS$10.5MSep 30, 2026
Candriam S.C.A.490KUS$10.6MSep 30, 2026
Citadel474KUS$10.2MSep 30, 2026
Dimensional438KUS$9.43MSep 30, 2026
Nuveen437KUS$9.39MSep 30, 2026
Parkman Healthcare Partners LLC396KUS$8.53MSep 30, 2026
Rock Springs Capital Management LP367KUS$7.9MSep 30, 2026
Federated Hermes, Inc.306KUS$6.58MSep 30, 2026
Alerus Financial NA300KUS$6.45MSep 30, 2026
BNY297KUS$6.39MSep 30, 2026
Universal- Beteiligungs- und Servicegesellschaft mbH286KUS$6.14MSep 30, 2026
Ikarian Capital, LLC285KUS$6.13MSep 30, 2026
Kennedy Capital Management LLC281KUS$6.05MSep 30, 2026
Qube Research & Technologies Ltd280KUS$6.01MSep 30, 2026
Invesco258KUS$5.55MSep 30, 2026
Granahan Investment Management, LLC250KUS$5.38MSep 30, 2026
Tidal Investments LLC236KUS$5.07MSep 30, 2026
Tema ETFS LLC236KUS$5.07MSep 30, 2026
Sei Investments Co207KUS$4.45MSep 30, 2026
Burkehill Global Management, LP200KUS$4.3MSep 30, 2026

This page holds 50 of 200 holders. Open Shareholders

Funds

HolderSharesValueAs of
T. Rowe Price Small-Cap Stock Fund, Inc.7.18MUS$152MJun 30, 2026
Fidelity Growth Company Fund4.74MUS$103MMay 31, 2026
T. Rowe Price Institutional Small-Cap Stock Fund3.91MUS$82.8MJun 30, 2026
Vanguard Health Care Fund3.7MUS$84.3MJul 31, 2026
PRIMECAP Odyssey Aggressive Growth Fund3.69MUS$84.1MJul 31, 2026
Vanguard Total Stock Market Index Fund3.22MUS$68.3MJun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF2.99MUS$63.4MJun 30, 2026
iShares Russell 2000 ETF2.75MUS$58.2MJun 30, 2026
Select Biotechnology Portfolio2.13MUS$46.5MMay 31, 2026
T. Rowe Price Small-Cap Value Fund, Inc.1.63MUS$34.4MJun 30, 2026
Show 50 holders
HolderSharesValueAs of
Fidelity Growth Company K6 Fund1.36MUS$29.8MMay 31, 2026
Fidelity Series Growth Company Fund1.24MUS$27.1MMay 31, 2026
Vanguard Extended Market Index Fund1.22MUS$25.9MJun 30, 2026
Fidelity Small Cap Index Fund1.15MUS$26.2MJul 31, 2026
T. Rowe Price Health Sciences Fund, Inc.1.09MUS$23.2MJun 30, 2026
iShares Russell 2000 Growth ETF973KUS$20.6MJun 30, 2026
JPMorgan Small Cap Growth Fund774KUS$16.4MJun 30, 2026
Fidelity Extended Market Index Fund536KUS$11.7MMay 31, 2026
SmallCap Fund528KUS$12MJul 31, 2026
Vanguard Russell 2000 Index Fund524KUS$11.4MMay 31, 2026
Schwab U.S. Small-Cap ETF496KUS$10.8MMay 31, 2026
Driehaus Small Cap Growth Fund384KUS$8.14MJun 30, 2026
Tema Oncology ETF316KUS$6.89MMay 31, 2026
Driehaus Micro Cap Growth Fund306KUS$6.48MJun 30, 2026
BlackRock Health Sciences Opportunities Portfolio289KUS$6.3MMay 29, 2026
Vanguard Health Care Index Fund282KUS$6.15MMay 31, 2026
Fidelity Contrafund269KUS$5.71MJun 30, 2026
Schwab Small-Cap Index Fund256KUS$5.83MJul 31, 2026
JPMorgan Small Cap Blend Fund246KUS$5.21MJun 30, 2026
T. Rowe Price Spectrum Moderate Growth Allocation Fund206KUS$4.49MMay 31, 2026
Fidelity Total Market Index Fund197KUS$4.31MMay 31, 2026
Master Small Cap Index Series197KUS$4.18MJun 30, 2026
Vanguard Explorer Fund178KUS$4.05MJul 31, 2026
Fidelity Series Total Market Index Fund158KUS$3.44MMay 31, 2026
Adara Smaller Companies Fund149KUS$3.25MMay 31, 2026
iShares Core S&P Total U.S. Stock Market ETF144KUS$3.06MJun 30, 2026
Nuveen Small Cap Blend Index Fund139KUS$3.17MJul 31, 2026
The Hartford Healthcare Fund136KUS$3.09MJul 31, 2026
Optimum Small-Mid Cap Growth Fund135KUS$2.87MJun 30, 2026
T. Rowe Price New Horizons Fund, Inc.128KUS$2.71MJun 30, 2026
Vanguard U.S. Momentum Factor ETF128KUS$2.79MMay 31, 2026
Victory Small Cap Stock Fund126KUS$2.88MJul 31, 2026
Multi-Manager Small Cap Equity Strategies Fund123KUS$2.68MMay 31, 2026
Small Cap Value Portfolio118KUS$2.51MJun 30, 2026
EQ/2000 Managed Volatility Portfolio115KUS$2.43MJun 30, 2026
Dimensional U.S. Small Cap ETF106KUS$2.41MJul 31, 2026
Column Small Cap Select Fund102KUS$2.22MMay 31, 2026
Direxion Daily S&P Biotech Bull 3X Shares102KUS$2.31MJul 31, 2026
Federated Hermes MDT Small Cap Growth Fund99,392US$2.26MJul 31, 2026
Fidelity Small Cap Growth Index Fund98,771US$2.09MJun 30, 2026

This page holds 50 of 214 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Higgins Jack
Officer: Chief Scientific Officer
Sale13,200USD 25.32US$334KSep 11, 2026
Barchas Isaac
Director
Sale11,048USD 27.25US$301KAug 12, 2026
Barchas Isaac
Director
Sale62,291USD 26.23US$1.63MAug 11, 2026
Barchas Isaac
Director
Sale10,125USD 26.07US$264KAug 10, 2026
Barchas Isaac
Director
Sale15,248USD 26.06US$397KAug 7, 2026
Barchas Isaac
Director
Sale20,840USD 26.06US$543KAug 6, 2026
Horn Kinney
Officer: CHIEF BUSINESS OFFICER
Sale90,616USD 25.09US$2.27MAug 4, 2026
Horn Kinney
Officer: CHIEF BUSINESS OFFICER
Sale1,092USD 25.00US$27,300Jul 7, 2026
Barchas Isaac
Director
Sale16,906USD 24.20US$409KJul 7, 2026
Barchas Isaac
Director
Sale83,094USD 24.11US$2MJul 6, 2026
All 28 trades
TradeTradeSharesPriceValueDate
Lechleider Robert
Officer: Chief Medical Officer
Sale22,714USD 21.95US$499KJul 2, 2026
Lechleider Robert
Officer: Chief Medical Officer
Sale16,214USD 22.76US$369KJul 2, 2026
Lechleider Robert
Officer: Chief Medical Officer
Sale16,072USD 23.44US$377KJul 2, 2026
Barchas Isaac
Director
Sale75,665USD 22.35US$1.69MJul 2, 2026
Barchas Isaac
Director
Sale24,335USD 23.33US$568KJul 2, 2026
Barchas Isaac
Director
Sale101,050USD 21.12US$2.13MJun 30, 2026
Lechleider Robert
Officer: Chief Medical Officer
Sale40,580USD 19.56US$794KJun 25, 2026
Lechleider Robert
Officer: Chief Medical Officer
Sale14,420USD 20.66US$298KJun 25, 2026
Rosett Max
Officer: Chief Financial Officer
Sale60,000USD 18.23US$1.09MJun 15, 2026
Bienaime Jean Jacques
Director
Sale500USD 19.44US$9,720Jun 5, 2026
Bienaime Jean Jacques
Director
Sale10,000USD 19.41US$194KJun 5, 2026
Bienaime Jean Jacques
Director
Buy6,000USD 19.48US$117KJun 5, 2026
Bienaime Jean Jacques
Director
Buy3,500USD 19.46US$68,110Jun 5, 2026
Bienaime Jean Jacques
Director
Buy1,000USD 19.27US$19,270Jun 5, 2026
Bienaime Jean Jacques
Director
Buy5,000USD 20.70US$104KMay 15, 2026
Higgins Jack
Officer: Chief Scientific Officer
Sale9,438USD 21.64US$204KApr 2, 2026
Rosett Max
Officer: Chief Financial Officer
Sale63,656USD 21.91US$1.39MApr 2, 2026
Rosett Max
Officer: Chief Financial Officer
Sale1,344USD 22.48US$30,213Apr 2, 2026

Big stakes

StakeStakeSharesDateFiling
T. Rowe Price Investment Management, Inc.17.40%19.7MJun 30, 2026Schedule 13G
FMR LLC15.00%13.1MSep 30, 2025Schedule 13G
Wellington Management Group LLP5.30%6.04MSep 30, 2026Schedule 13G
Vanguard Capital Management LLC5.04%5.73MSep 30, 2026Schedule 13G
Enavate Sciences Gp, LLC4.30%4.77MDec 18, 2025Schedule 13D
Janus Henderson Group PLC2.20%1.91MMar 31, 2025Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Jean-Jacques Bienaimé
Other companies: Ascendis Pharma A/S (Director · Since at least Mar 23, 2026); Keros Therapeutics, Inc. (Director · Since at least Jun 1, 2024); Incyte Corporation (Director · Since at least Jan 20, 2015); Immunic, Inc. (Director · Apr 16, 2014 – Sep 24, 2018 · Past); Portola Pharmaceuticals Inc (Director · May 21, 2013 – May 16, 2014 · Past); InterMune Inc (Director · Mar 26, 2012 – Sep 29, 2014 · Past); NeurogesX Inc (Director · May 1, 2007 – Feb 7, 2012 · Past); BioMarin Pharmaceutical Inc. (Director · Jan 3, 2006 – May 20, 2024 · Past)
Director · Since at least Nov 7, 2023
Clay Siegall
Other companies: Shattuck Labs, Inc. (President, Chairman of the Board of Immunome, Inc. · Since at least Mar 1, 2024); Tourmaline Bio Inc. (Director · Since at least Dec 13, 2023); Nurix Therapeutics, Inc. (Director · May 28, 2021 – May 5, 2022 · Past); Synlogic Inc (Director · Sep 30, 2015 – Jun 29, 2016 · Past); Alder BioPharmaceuticals Inc (Director · May 7, 2014 – Oct 22, 2019 · Past); Ultragenyx Pharmaceutical Inc. (Director · Jan 30, 2014 – Aug 7, 2020 · Past); Seagen Inc (President & CEO, Director · Jan 31, 2006 – May 12, 2022 · Past)
President & Chief Executive Officer · Since at least Oct 2, 2023
Richard F Fitzgerald
Other companies: 22nd Century Group, Inc (Chief Financial Officer · Nov 15, 2021 – Mar 21, 2022 · Past); Nauticus Robotics, Inc. (Chief Financial Officer · Jul 14, 2021 – Jul 14, 2021 · Past); Sesen Bio Inc (Chief Financial Officer · Feb 21, 2019 – Feb 21, 2019 · Past); Eleven Biotherapeutics Inc (Chief Financial Officer · Oct 20, 2017 – Apr 9, 2018 · Past); PAVmed Inc. (CFO and Secretary · Jan 29, 2016 – Jun 1, 2016 · Past); TechPrecision Corporation (Chief Financial Officer · Jun 13, 2013 – Aug 12, 2015 · Past)
Chief Financial Officer · Oct 1, 2020 – Oct 1, 2020 · Past
Carol A. Schafer
Other companies: Kura Oncology, Inc. (Director · Since at least Jun 3, 2021); Repare Therapeutics Inc (Director · Since at least May 13, 2021); Insmed Incorporated (Director · Since at least May 12, 2021); Five Prime Therapeutics Inc (Director · Apr 16, 2021 – Apr 16, 2021 · Past); Aceragen Inc. (Director · Oct 1, 2020 – Jun 23, 2022 · Past)
Director · Since at least Jan 2, 2024
Franklyn Prendergast
Other companies: Lantern Pharma Inc. (Director · Since at least Jun 10, 2020); NeuBase Therapeutics Inc (Director · Jul 12, 2019 – Sep 9, 2022 · Past); Cancer Genetics Inc (Director · Apr 4, 2013 – Jul 23, 2019 · Past); Eli Lilly and Company (Director · Nov 30, 2006 – Nov 20, 2017 · Past)
Director · Jun 16, 2021 – Oct 2, 2023 · Past
James Boylan
Other companies: CAMP4 Therapeutics Corporation (Director · Since at least Oct 10, 2024); Zenas BioPharma, Inc. (Director · Since at least Sep 12, 2024); Compass Therapeutics, Inc. (Director · Since at least Nov 4, 2022)
Director · Since at least Oct 2, 2023
John Higgins
Other companies: OmniAb, Inc. (Board Chair · Since at least Nov 1, 2022); Bio-Techne Corp (Director · Since at least Jun 4, 2019); Ligand Pharmaceuticals Incorporated (Director · May 14, 2019 – Dec 28, 2022 · Past)
Chief Scientific Officer · Since at least Oct 2, 2023
John L. LaMattina
Other companies: Ligand Pharmaceuticals Incorporated (Director · Since at least May 31, 2012); Larimar Therapeutics, Inc. (Director · Jun 18, 2014 – Jun 26, 2019 · Past); Human Genome Sciences Inc (Director · May 17, 2012 – Jul 30, 2012 · Past)
Director · Oct 1, 2020 – Jun 8, 2023 · Past
Corleen Roche
Other companies: Iovance Biotherapeutics, Inc. (Chief Financial Officer · Since at least Jul 15, 2025); CG Oncology, Inc. (CFO · Jan 24, 2024 – Apr 15, 2025 · Past)
Chief Financial Officer · Apr 19, 2021 – Jun 8, 2023 · Past
Bob Lapetina
Other companies: CG Oncology, Inc. (See Remarks · Since at least Aug 5, 2025)
PAO and VP Finance & Corporate · Jan 2, 2024 – Jan 2, 2024 · Past
All 32 people
PersonSeat
Isaac Barchas
Other companies: TMC The Metals Company Inc. (Director · May 5, 2020 – May 5, 2020 · Past)
Lead Independent Director and Director · Since at least Oct 2, 2023
Kinney Horn
Other companies: Olema Pharmaceuticals, Inc. (Chief Business Officer · Jun 10, 2020 – Feb 1, 2023 · Past)
CHIEF BUSINESS OFFICER · Since at least Feb 12, 2024
Philip Wagenheim
Other companies: Swarmer, Inc (Director · Since at least Mar 16, 2026)
Director · Since at least Jun 10, 2025
Richard A Baron
Other companies: Zynerba Pharmaceuticals Inc (Chief Financial Officer · Aug 4, 2015 – Sep 11, 2015 · Past)
Director · Oct 1, 2020 – Jun 8, 2023 · Past
Sandra M. Swain
Other companies: Seagen Inc (Director · Nov 9, 2022 – Dec 14, 2023 · Past)
Director · Since at least Apr 25, 2024
Bob LechleiderChief Medical Officer · Since at least Jul 27, 2026
Bruce TurnerChief Strategy Officer · Oct 2, 2023 – Aug 9, 2024 · Past
Dennis H GiesingChief Development Officer · Mar 23, 2021 – Jun 8, 2023 · Past
Jack HigginsChief Scientific Officer · Since at least Oct 23, 2025
Max RosettChief Financial Officer · Since at least Oct 2, 2023
Max RosettChief Financial Officer · Since at least Jul 27, 2026
Michael LefenfeldDirector · Oct 1, 2020 – Jun 8, 2023 · Past
Michael MorinChief Scientific Officer · Oct 1, 2020 – Oct 1, 2020 · Past
Michael RappDirector · Oct 1, 2020 – Oct 2, 2023 · Past
Michael WidlitzDirector · Oct 1, 2020 – May 28, 2021 · Past
Philip TsaiChief Technical Officer · Since at least Jun 17, 2024
Phil Noland RobertsChief Technology Officer · Dec 8, 2023 – Dec 13, 2023 · Past
Phil TsaiChief Technical Officer · Since at least Jul 27, 2026
Purnanand D SarmaPresident and CEO, Director · Oct 1, 2020 – Jun 8, 2023 · Past
Robert LechleiderChief Medical Officer · Since at least Oct 16, 2023
Roee ShaharEVP, Commercial · Since at least Nov 5, 2026
Sandra StonemanCHIEF LEGAL OFFICER & GC · Since at least Oct 26, 2020

Open People

Log in to ask 6ix AI your own questions about Immunome, Inc.